NR566 Week 1 Study Outline

NR566 Week 1 Study Outline Many questions are written to assess your clinical application of the material from the textbook, in real-world scenarios. Chapter 21: Drugs Affecting the Endocrine System • Know the pharmacodynamics, pharmacotherapeutics clinical use, drug interactions and adverse drug reactions for: 
o Biphosphonates
 The remodeling cycle is initiated by osteoclastic activity. In response to microfractures and other damage associated with normal wear and tear, osteoclasts are drawn to the damaged area of the trabecula, attach to its surface, and resorb the damaged and surrounding bone, creating a resorption pit (Fig. 21-1). Resorption is accomplished by pseudopodia, which attach tightly to the bone surface and secrete acids and enzymes that dissolve bone. The osteoclasts then leave the area and osteoblasts move in, line up to cover the surface of the pit, and form new bone. • Bisphosphonates adhere tightly to bone and, by inhibiting osteoclastic activity, are potent inhibitors of both normal and abnormal bone resorption. Etidronate, pamidronate, risedronate, alendronate (Fosamx), tiludronate, Ibandronate (bonvia) , zoledronic acid 8 oz of water with drug, and remain upright for one hour pregnancy c except pamidronate and zoledronic acid preg D no chidren no absoluate contraindications except uncorrect hypocalcemia, barretts esophagus and renal insufficiency etidronate avoid with entercolitis, , fractures with pagets disease, all ADRs is musculoskeletal pain , rare reports for osteonecrosis, increased risk for AFIB, GI distress, dyspepsia drug interactions: most common with drugs that affect the GI tract, H2 blocking agents, Ca supplements, antacids interfere with absorption, GI bleed increased risk when on NSAIDS an aspirin, Used for osteoporosis, pagets disease, spinal cord injurys etidronate, postmenopausal women, glucocorticoid induced osteoporosis • o Aromatase inhibitors
 • o Growth hormones
 ……………………………………………CONTINUED…………………………………..